Switch theme
Sign up to access all valuation multiples
CSL is one of the largest global biotech companies and has two main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders and neurological indications. Seqirus is now the world’s second largest influenza vaccination business and was acquired in fiscal 2015. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
1991
32K+
LTM Revenue $24.1B
LTM EBITDA $8.1B
$87.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
CSL has a last 12-month revenue (LTM) of $24.1B and a last 12-month EBITDA of $8.1B.
In the most recent fiscal year, CSL achieved revenue of $9.4B and an EBITDA of $3.0B.
CSL expects next 12-month revenue of XXX and NTM EBITDA of XXX
See CSL valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $24.1B | XXX | $9.4B | XXX | XXX | XXX |
| Gross Profit | $13.3B | XXX | $4.9B | XXX | XXX | XXX |
| Gross Margin | 55% | XXX | 51% | XXX | XXX | XXX |
| EBITDA | $8.1B | XXX | $3.0B | XXX | XXX | XXX |
| EBITDA Margin | 34% | XXX | 32% | XXX | XXX | XXX |
| EBIT | $6.9B | XXX | $1.8B | XXX | XXX | XXX |
| EBIT Margin | 29% | XXX | 19% | XXX | XXX | XXX |
| Net Profit | $4.9B | XXX | $1.7B | XXX | XXX | XXX |
| Net Margin | 20% | XXX | 18% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $13.5B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, CSL's stock price is AUD 247 (or $159).
CSL has current market cap of AUD 120B (or $76.8B), and EV of AUD 136B (or $87.3B).
See CSL trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $87.3B | $76.8B | XXX | XXX | XXX | XXX | $6.45 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, CSL has market cap of $76.8B and EV of $87.3B.
CSL's trades at 7.0x EV/Revenue multiple, and 21.1x EV/EBITDA.
Equity research analysts estimate CSL's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
CSL has a P/E ratio of 24.4x.
See valuation multiples for CSL and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $76.8B | XXX | $76.8B | XXX | XXX | XXX |
| EV (current) | $87.3B | XXX | $87.3B | XXX | XXX | XXX |
| EV/Revenue | 5.6x | XXX | 7.0x | XXX | XXX | XXX |
| EV/EBITDA | 16.8x | XXX | 21.1x | XXX | XXX | XXX |
| EV/EBIT | 19.7x | XXX | 27.9x | XXX | XXX | XXX |
| EV/Gross Profit | 10.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | 24.4x | XXX | 31.5x | XXX | XXX | XXX |
| EV/FCF | 36.0x | XXX | 50.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCSL's last 12 month revenue growth is 6%
CSL's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
CSL's rule of 40 is 37% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
CSL's rule of X is 49% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for CSL and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 6% | XXX | 17% | XXX | XXX | XXX |
| EBITDA Margin | 34% | XXX | 33% | XXX | XXX | XXX |
| EBITDA Growth | 10% | XXX | 41% | XXX | XXX | XXX |
| Rule of 40 | 37% | XXX | 39% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 49% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 11% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 10% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 33% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
CSL acquired XXX companies to date.
Last acquisition by CSL was XXXXXXXX, XXXXX XXXXX XXXXXX . CSL acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was CSL founded? | CSL was founded in 1991. |
| Where is CSL headquartered? | CSL is headquartered in Australia. |
| How many employees does CSL have? | As of today, CSL has 32K+ employees. |
| Who is the CEO of CSL? | CSL's CEO is Dr. Paul McKenzie. |
| Is CSL publicy listed? | Yes, CSL is a public company listed on ASX. |
| What is the stock symbol of CSL? | CSL trades under CSL ticker. |
| When did CSL go public? | CSL went public in 1994. |
| Who are competitors of CSL? | Similar companies to CSL include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of CSL? | CSL's current market cap is $76.8B |
| What is the current revenue of CSL? | CSL's last 12 months revenue is $24.1B. |
| What is the current revenue growth of CSL? | CSL revenue growth (NTM/LTM) is 6%. |
| What is the current EV/Revenue multiple of CSL? | Current revenue multiple of CSL is 5.6x. |
| Is CSL profitable? | Yes, CSL is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of CSL? | CSL's last 12 months EBITDA is $8.1B. |
| What is CSL's EBITDA margin? | CSL's last 12 months EBITDA margin is 34%. |
| What is the current EV/EBITDA multiple of CSL? | Current EBITDA multiple of CSL is 16.8x. |
| What is the current FCF of CSL? | CSL's last 12 months FCF is $3.8B. |
| What is CSL's FCF margin? | CSL's last 12 months FCF margin is 16%. |
| What is the current EV/FCF multiple of CSL? | Current FCF multiple of CSL is 36.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
